Hence, studying the “ON/OFF” of the major tumor-driving EGFR/K-RAS/MAPK/SIAH pathway may represent an opportunity to risk-stratify TNBC patients before and after NACT/NST (IO-therapy). The gene discussed is KRAS; the disease is neoplasm.